Biodesix, Inc. today announced new data regarding VeriStrat®, a serum proteomic test, and epidermal growth factor receptor mutation status in a Phase 1B/2 study of cabozantinib +/- erlotinib in advanced non-small cell lung cancer that is being presented at the World Conference on Lung Cancer.
Details of the presentation are as follows:
MINI 08 – Prognostic/Predictive Biomarkers (ID106)
Moderators: Thomas E. Stinchcombe, Nick Pavlakis
WCLC 2015, 09/07/2015, 04:45 PM – 06:15 PM, Mile High Ballroom 4a-4f
MINI08.04 – VeriStrat® and Epidermal Growth Factor Receptor Mutation Status in a Phase 1B/2 study of Cabozantinib +/- Erlotinib in Non-Small Cell Lung Cancer.
Authors: Sukhmani K. Padda, Primo Lara Jr., Scott N. Gettinger, Jeffrey A. Engelman, Pasi A. Jänne, Howard West, Lisa Y. Zhou, Deepa S. Subramaniam, Joseph W. Leach, Michael B. Wax, Joel W. Neal, Douglas O. Clary, Laurie J. Goodman. Heather A. Wakelee
VeriStrat and Biodesix are registered trademarks of Biodesix, Inc. All other trademarks referenced herein are the property of their respective owners.
Biodesix’ diagnostic tests are used for earlier disease detection, more accurate diagnosis, disease monitoring and better therapeutic guidance, leading to improved outcomes for cancer patients. The company currently has two tests available to clinicians, GeneStrat™ and VeriStrat®. Used for tumor profiling, GeneStrat is an a la carte gene panel of clinically actionable mutations. VeriStrat, a serum proteomic test, provides physicians with prognostic and predictive information to improve treatment decisions. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics to improve the utility of therapeutic agents.